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Contrast enhanced multi-detector CT (MD CT) is now
the most commonly used imaging modality for detection
of liver metastases and work-up of equivocal lesions
found at ultrasound. MR imaging is an established tech-
nique for non-invasive characterisation of liver masses
and for preoperative potentially resectable liver tumours.
Diagnostic value of each modality strongly depends on
the scan technique. With MDCT, the role of thin slice
imaging has been well established, with slice thicknesses
of 5–7.5 mm being inferior to thinner slices in terms of
lesion detection [1]. The amount of contrast material as
well as the flow rate influence enhancement of hyper-
vascular lesions in the arterial phase and the magnitude
of liver parenchyma enhancement in the venous phase,
respectively [2,3]. The number of CT scans varies with
the local indication, with single-phasic venous scans to
4-phasic scans, as recommended by European and US
guidelines for HCC detection and characterisation.
For MR imaging, a multi-point DIXON technique has
replaced conventional T1-weighted GRE pulse sequences;
with this technique in one breathhold in-phase, opposed-
phase, fat-suppressed, and water-suppressed images can
be obtained, without any spatial misregistration. Diffusion-
weighted pulse sequences significantly improve detection
of metastases [4,5]. As a black-blood technique with T2-
weighted image impression, it demonstrates small lesions
without any blurring by an adjacent high signal intensity
of vessels of bile ducts [6]. Administration of contrast
agents is mandatory for liver MRI, with the choice of
either non-specific gadolinium chelates or liver specific
contrast agents. Indications for liver-specific contrast
agents include preoperative evaluation of liver metastases
and characterisation of hepatocellular lesions (FNH, ade-
noma), whereas non-specific gadolinium chelates are used
for characterisation of haemangiomas, after liver resection
or tumour ablation. The choice of the imaging techniques
and the scan or contrast agent protocol should be tailored
according to the clinical question.
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